At Synbio Technologies, we understand the importance of developing safe and effective vaccines for the betterment of public health. Adenovirus (AdV) is a powerful tool that has been widely utilized in a variety of fields, including gene therapy, tumor treatment, and vaccine development due to its high genetic stability, low pathogenicity, and ability to produce high titer and purity.

First discovered in the 1980s, adenovirus has been extensively studied as a gene delivery vector and was the first viral gene delivery vector used in humans. This is due to its high efficiency of gene transduction in various cells, as well as its ability to integrate viral genomic DNA into the host cell chromosome. Adenovirus is industrially produced on a large scale and is mostly used in the field of oncolytic virus therapy as well as the expression of vaccine antigens.

We specialize in utilizing the power of adenovirus gene synthesis in the development of safe and effective vaccines. We understand the challenges and complexities of gene synthesis, and we utilize the latest techniques and methods to ensure accurate gene sequences. With our expertise, we can help accelerate the development of new vaccines and provide innovative solutions to public health challenges.

In recent years, we have seen the development of highly effective adenovirus vector vaccines for diseases like Ebola and influenza. In fact, the first viral vector vaccine to enter clinical trials worldwide was the human adenovirus vector COVID-19 vaccine (Ad5-nCoV) developed in China.

Since then, countries like the United Kingdom and Russia have also developed adenovirus vector vaccines that have shown remarkable success in clinical trials. These vaccines have demonstrated rapid cellular and humoral immunity after vaccination, especially in severe patients, with protective rates of more than 90%.

As we face the ongoing COVID-19 pandemic, adenovirus vector vaccines targeting the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) have been authorized for emergency use. These vaccines have played a crucial role in mitigating the spread of COVID-19 and have offered hope for a return to normalcy.

The ongoing evolution of neo-coronaviruses highlights the urgent need for effective vaccines that can keep pace with emerging strains. Adenovirus vector vaccines, which utilize the power of gene synthesis to insert the gene of COVID-19 into the adenovirus vector, represent a promising solution. By expressing the antigen of COVID-19 without producing its toxicity, these vaccines can help the human body recognize and generate specific immunity against the virus.

Ad5-nCoV Structure Diagram

Synbio Technologies has accumulated extensive experience in total synthesis technology, enabling us to synthesize any adenovirus genome and achieve high-quality plasmid manufacturing in a remarkably short turnaround time. Our expertise in adenovirus gene synthesis has been crucial in the development of adenovirus vector vaccines, allowing us to contribute to the fight against COVID-19 and other public health challenges.

We recognize that the power of adenovirus extends far beyond the realm of vaccine development. Modified oncolytic adenoviruses, in particular, offer many advantages and have become a focus of virus research. In fact, China’s Food and Drug Administration approved the world’s first oncolytic adenovirus for the treatment of tumor patients in 2005, setting off a wave of oncolytic adenovirus research from the laboratory to clinical transformation.

At Synbio Technologies, we have synthesized a range of adenovirus genomes exceeding 30 kb for customers worldwide. This has provided an effective way to realize large-scale modification of recombinant adenovirus genomes, ultimately improving their safety and therapeutic effect. Our commitment to excellence in adenovirus gene synthesis continues to drive breakthroughs in vaccine development and disease treatment, as we work to build a healthier, safer future for all.

Accelerate Your COVID-19 Vaccine Research with Our Adenovirus Genome Synthesis Services.